Publication date: Dec 14, 2024
To identify demographic, clinical and immunological factors associated with adverse COVID-19 outcomes. A large randomised controlled trial of ChAdOx1 nCoV-19 was undertaken in Brazil. Participants were randomised 1:1 either to receive ChAdOx1 nCov-19 or to a control group. COVID-19 infections were confirmed by nucleic acid amplification test (NAAT) and classified using the WHO clinical progression scale. Anti-spike antibody responses and serum neutralising activity were measured 28 days after second vaccination in some participants. Exploratory analyses were conducted into factors associated with COVID-19 infection severity and hospitalisation, using logistic regression models adjusted for demographic and clinical factors. 10,416 participants were enrolled; 1790 had NAAT-positive COVID-19 infection; 63 cases required hospitalisation. More severe infection was associated with greater body-mass index (BMI) (odds ratio [OR] = 1. 06 [95 %CI: 1. 01-1. 10], p = 0. 01) and diabetes (OR = 3. 67 [1. 59-8. 07], p = 0. 003). Hospitalisation risk increased with greater age (OR = 1. 06 [1. 03-1. 08], p
Open Access PDF
Concepts | Keywords |
---|---|
28days | Coronavirus |
Brazil | Epidemiology |
Diabetes | Immunisation |
Randomised | Pandemic |
Vaccination | Vaccine effectiveness |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | SARS-CoV-2 infections |
disease | MESH | infections |
disease | IDO | nucleic acid |
disease | MESH | clinical progression |
disease | IDO | infection |
disease | MESH | Long Covid |